Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Brief introduction:
The company was separated from Pharmacia in 1998 and listed on NASDAQ in Sweden. Its main business is the development of immune defense drugs and therapies for cancer and inflammatory diseases. Currently, the company mainly provides oral active immunomodulatory molecular drugs and antibode-based immunotherapies.
Experience Advantage:
The company has extensive experience in drug development from early to late stage clinical development and is partnered with renowned Neotx Therapeutics Ltd. A partnership has been established to develop a commercial product for the estrogenic treatment of cancer with nattozumab.
In early 2020, the company announced a new direction for the clinical development of its Naptumomab technology for the treatment of solid tumors.
Tasquinimod is also in Phase Ib/II development in advanced cancer and in clinical development of Tasquinimod in multiple myeloma.
The company's program also includes Laquimod for the treatment of eye diseases uveitis and wet AMD, and plans to begin clinical development in the second half of 2021.
Cooperation Intention:
The company is now looking for a Chinese research and development partner.